macquarie - sirtex new recommendation to buy, page-39

sirtex upcoming conferences,... With Bioshares , Huntleys, Hunter Hall, and Macquarie and others getting behind the Sirtex share, there will be alot of self generated momentum from the earnings growth, and new positive clincal trial data that will be given over the next several weeks. With new Australian reimbursement already secured , and European reimbursement coming, this will fuel more growth. The bulk of earnings momentum will be generated from the new radiation oncologists learning and performing the procedures in their local hospitals as there is only 5-8% of US oncologists who are trained or aware of the Sir Spheres treatment.In addition there are new indications for the product in different tumor types that havegone to the liver which is a huge new market opportunity for the company. There are alot of positive developments being generated after all the hard work of the last 20 years by Dr Gray and in the last three years by the Sirtex managemnet team, and all these positive changes will ultimately be reflected in a quicker than many anticipate appreciation of the sp in the near term.Expecting $4.25-$5 near term. Then as the backwards analysts figure out what many on this board have started to realize a while ago they should jump on the bandwagon and send sp over $5+. My opinion after being in the industry a while. Do your own work.